[Editor's note: This article was updated on 1 December to include more comments from Wall Street analysts that were published late on 30 November.]
Johnson & Johnson Medtech/Biosense Webster is acquiring Laminar, the California-based developer of a novel transcatheter device that eliminates the left-atrial
On 30 November, J&J announced that it has completed a deal to buy Laminar for an upfront payment of $400m, plus “additional potential clinical and regulatory milestone payments” beginning in 2024